Basic Information:

  VIRBase ID:  

HHID00047937

  Virus:  

Human gammaherpesvirus 4 (Epstein-Barr virus, EPV)

  Host:  

Homo sapiens

  Confidence Score:  

0.4752

  Interaction Type:  

Host-Host interaction

  Predicted Binding:

 

      hsa-miR-30c-5p:  MIMAT0000244          MZT1:  NM_001071775     

      *It may take a few minutes to display results.

Interactor Information:

	Interactor1	Interactor2
Symbol	hsa-miR-30c-5p	MZT1
miRBase Accession/Entrez ID	MIMAT0000244	440145
Organism	Homo sapiens	Homo sapiens
Category	miRNA	mRNA
Alias	-	C13orf37//MOZART1

ncRNA SNP information:

Resource	Symbol	SNP ID	SNP Position	Ref/Alt
miRNASNP-v3	hsa-miR-30c-5p	rs1273660120 chr1:40757310    C/G rs757010411 chr1:40757312    A/G rs778882994 chr1:40757318    T/G rs113749278 chr6:71377017    A/G rs113749278 chr6:71377017    A/T rs1290581693 chr6:71377003    G/A rs1296517452 chr6:71377016    G/T rs1360882118 chr6:71377008    G/C rs369489437 chr6:71377011    T/C rs374192008 chr6:71377013    T/C rs1357662785 chr6:71377024    C/T

RNA Editing:

Resource	Symbol	Editing Position	Change	Genetic Region
RADAR	MZT1	chr13:73299074(-) A-I      intronic chr13:73290177(-) A-I      intronic chr13:73299141(-) A-I      intronic chr13:73299078(-) A-I      intronic chr13:73298749(-) A-I      intronic chr13:73292889(-) A-I      intronic chr13:73292896(-) A-I      intronic

RNA Modification:

Resource	Symbol	ModificationPosition	Type	Genomic Context	PMID
RMBase	MZT1	chr13:73283631-73283632(-) m6A 3'UTR       27773535 chr13:73283638-73283639(-) m6A 3'UTR       27773535 chr13:73283784-73283785(-) m6A 3'UTR       27773535 chr13:73283794-73283795(-) m6A 3'UTR       27773535 chr13:73301670-73301671(-) m6A CDS       24209618

RNA Localization:

Resource	Symbol	Subcellular Localization	Tissue or Cell Line	PMID
RNALocate	hsa-miR-30c-5p	Cytoplasm Nasopharyngeal carcinoma cells     20498841 Cytoplasm Cell line (HeLa)     21695135 Cytoplasm Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa)     24918059 Exosome Human cervical cancer cell line (HeLa)     25760330 Exosome Breast cancer cell line (MCF-7)     20976003 Exosome Primary dendritic cells|T cell line (J77)     21505438 Exosome Brain tissue     23382797 Exosome Plasma     23663360 Exosome Human mast cell line (HMC-1)     24009880 Exosome Blood|B lymphoblastoid cells|Breast milk|Endothelial cells|Epithelial cells|Lymphoma tissue|Mast cells|Seminal fluid|Tongue tissue     - Microvesicle Seminal plasma     23539611 Microvesicle Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine     - Mitochondrion Skeletal muscle myoblasts     21637849 Mitochondrion Cell line (HEK-293|HeLa)     22984580 Nucleolus Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa)     24918059 Nucleus Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa)     24918059 Nucleus Nasopharyngeal carcinoma cells     20498841 Nucleus Colon adenocarcinoma cells     20864815 Nucleus Neural progenitor cells     21363885
	MZT1	Cytosol Human myelogenous leukemia cell line (K-562)     21613539 Cytosol K562 cells     - Exosome Blood     - Ribosome Colon cancer cells     24393600

Related Drug Information:

Resource	Symbol	Drug Name	PubChem ID	Function
ncDR	hsa-miR-30c-5p	2-Amino-3H-phenoxazin-3-one 72725 Drug resistant Resorufin 69462 Drug resistant Hopeaphenol 495605 Drug resistant 2,3-Dimethylbenzo[g]quinoxaline-5,10-dione 353644 Drug resistant 6,7-Dimethoxy-4-(3-hydroxy-4-methylanilino)quinazoline hydrochloride 21701565 Drug sensitive Erlotinib 176870 Drug sensitive (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate 10437018 Drug sensitive 1,2-benzo-8-(d,l-alanyl)-3-phenoxazone nitrate salt - Drug resistant 2-chloro-3-amino-5,8-dihydoxy-1,4-naphthoquinone - Drug resistant benzo[b]naphtho[2,3-d]furan-6,11-dione, 4-chloro-3-hydroxy - Drug resistant organosulfur compound - Drug sensitive

Resource	Symbol	Drug Name	PubChem ID	Function	Link
RNAInter	hsa-miR-30c-5p	Curcumin 969516 Drug interaction    RC00001607 Vincristine 5978 Drug interaction    RC00001599 Estradiol 5757 Drug interaction    RC00001598 Mitomycin 5746 Drug interaction    RC00001597 Eloxatine 5310940 Drug interaction    RC00001609 Imatinib 5291 Drug interaction    RC00001596 Morphine 5288826 Drug interaction    RC00001608 Docosahexaenoic acid 445580 Drug interaction    RC00001606 Cyclopamine 442972 Drug interaction    RC00001605 Carboplatinum 38904 Drug interaction    RC00001603 Paclitaxel 36314 Drug interaction    RC00001602 Doxorubicin 31703 Drug interaction    RC00001601 cis-Diaminedichloroplatinum 2767 Drug interaction    RC00001595 Arsenic trioxide 14888 Drug interaction    RC00001600 Gefitinib 123631 Drug interaction    RC00001604 platinum-based doublet chemotherapy - Drug interaction    RC00001610 TRAIL therapy - Drug interaction    RC00001611 Hydroxamic acid HDACi LAQ824 - Drug interaction    RC00001612 Trastuzumab - Drug interaction    RC00001613

Resource	Symbol	Drug Name	PubChem ID	PMID
NoncoRNA	hsa-miR-30c-5p	Cisplatin 5702198       28222434

Interaction Network (The top 100 interactions):

Interactor1: hsa-miR-30c-5p
Interactor2: MZT1

Evidence Support:

Weak-Evidence	HITS-CLIP
Support Database	ViRBase

References:

PMID	22473208	Target region	3'UTR
Source	ViRBase	Interactor1 expression	None
Tissue or cell line	Jijoye cells	Interactor2 expression	None
Description	Our HITS-CLIP data yield 1185 human 3'UTRs targeted by members of the miR-17~92 cluster in Jijoye cells. Comparison to the 1664 3'UTRs targeted by EBV miRNAs reveals 740 shared genes (44% of EBV targets and 62% of miR-17~92 targets; Figure 6B and Supplementary Table 7). Thus, EBV miRNAs co-target a majority of miR-17~92 regulated mRNAs, which are assigned to a variety of pathways, most notably regulating transcription, apoptosis, and the cell cycle (Figure 6C). Similarly, other abundant immunologically relevant miRNAs, 142-3p and miR-155, co-target with EBV miRNAs a large fraction of their Ago-bound 3'UTRs, representing ~60% of the targets for each of these host miRNAs (Supplementary Figure 5).